6 NEWS
LSIPR Newsletter 12:14 Acne drug at centre of ‘first’ IPR ruling of its kind WASHINGTON, DC, US
Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.
Te US Patent and Trademark Office (USPTO) rejected arguments by generic company Amneal that three patents covering the drug should be declared invalid.
Amneal had hoped to launch a generic version of the drug, used to treat skin blemishes and bumps, and requested an inter partes review (IPR) at the office aſter unsuccessful litigation at the US District Court for the District of Delaware.
In its decision, issued on December 9, the USPTO’s Patent Trial and Appeal Board rejected arguments by Amneal that the patents covered obvious variations of earlier research.
Switzerland-based Galderma is the pharmaceutical arm of Nestlé’s skin care company Nestlé Skin Health.
According to Gerald Flattmann, partner at law firm Paul Hastings in New York, who represented the patent holders, this was the first time a pharmaceutical patent has been successfully defended through the IPR format.
“More and more of our clients’ pharmaceutical and biotech patents have been targeted in IPR proceedings. Terefore, it is increasingly important to navigate this challenging landscape with a winning strategy and a winning team,” said Flattmann.
He added: “Tis win effectively protects Galderma’s product Oracea against generic incursion through to 2027, when the patent in question expires.”
Amneal, which can appeal against the decision, did not respond to a request for comment. n
Wherever Innovations Are Created – Imitators Are Never Far Behind. We Take Care Of Innovators – And Imitators.
Since 1924, we’ve been protecting and defending intellectual property rights – in Germany and around the world. The fact that our practice regularly takes a leading position in independent rankings is not only due to our professional expertise – but also to our emphasis on building close partnerships with our clients. That’s why each of our clients is assigned a like-minded and personally compatible contact person for their individual support.
www.grunecker.de
130821_AZ_187x130_ENG.indd 1
www.lifesciencesipreview.com
21.08.13 15:51
OCSKAY BENCE /
SHUTTERSTOCK.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20